SIRPA and neoplasm: In addition, in an immunocompetent mouse glioma model, blocking the CD47-SIRPα axis by anti-CD47 antibody significantly increased phagocytosis of glioma cells and GSCs by macrophages, consequently inhibiting tumor growth and prolonging survival (104).